AU696460B2 - Use of fibroblast growth factors to stimulate bone growth - Google Patents

Use of fibroblast growth factors to stimulate bone growth Download PDF

Info

Publication number
AU696460B2
AU696460B2 AU61464/96A AU6146496A AU696460B2 AU 696460 B2 AU696460 B2 AU 696460B2 AU 61464/96 A AU61464/96 A AU 61464/96A AU 6146496 A AU6146496 A AU 6146496A AU 696460 B2 AU696460 B2 AU 696460B2
Authority
AU
Australia
Prior art keywords
fgf
bone
amount
heparin
growth factor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU61464/96A
Other languages
English (en)
Other versions
AU6146496A (en
Inventor
Wilson Burgess
Colin R Dunstan
Elizbieta Izbicka
Michael C. Jaye
Gregory Mundy
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
OsteoSA Inc
Aventis Pharmaceuticals Inc
Original Assignee
RHONE POULENC RORER PHARMA
OsteoSA Inc
Rhone Poulenc Rorer Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by RHONE POULENC RORER PHARMA, OsteoSA Inc, Rhone Poulenc Rorer Pharmaceuticals Inc filed Critical RHONE POULENC RORER PHARMA
Publication of AU6146496A publication Critical patent/AU6146496A/en
Application granted granted Critical
Publication of AU696460B2 publication Critical patent/AU696460B2/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/50—Fibroblast growth factor [FGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1825—Fibroblast growth factor [FGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0063—Periodont
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/14—Macromolecular materials
    • A61L27/22—Polypeptides or derivatives thereof, e.g. degradation products
    • A61L27/227—Other specific proteins or polypeptides not covered by A61L27/222, A61L27/225 or A61L27/24
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/50—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
    • A61L27/54—Biologically active materials, e.g. therapeutic substances
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/50—Fibroblast growth factor [FGF]
    • C07K14/501—Fibroblast growth factor [FGF] acidic FGF [aFGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
    • A61L2300/412—Tissue-regenerating or healing or proliferative agents
    • A61L2300/414—Growth factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2430/00—Materials or treatment for tissue regeneration
    • A61L2430/02—Materials or treatment for tissue regeneration for reconstruction of bones; weight-bearing implants
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/827—Proteins from mammals or birds
    • Y10S530/84—Bones; tendons; teeth; cartilage

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Dermatology (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Transplantation (AREA)
  • Oral & Maxillofacial Surgery (AREA)
  • Genetics & Genomics (AREA)
  • Nutrition Science (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Biomedical Technology (AREA)
  • Physiology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
AU61464/96A 1995-05-31 1996-05-29 Use of fibroblast growth factors to stimulate bone growth Ceased AU696460B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US454964 1995-05-31
US08/454,964 US5656598A (en) 1994-03-08 1995-05-31 Use of fibroblast growth factors to stimulate bone growth
PCT/US1996/007920 WO1996038167A1 (en) 1995-05-31 1996-05-29 Use of fibroblast growth factors to stimulate bone growth

Publications (2)

Publication Number Publication Date
AU6146496A AU6146496A (en) 1996-12-18
AU696460B2 true AU696460B2 (en) 1998-09-10

Family

ID=23806804

Family Applications (1)

Application Number Title Priority Date Filing Date
AU61464/96A Ceased AU696460B2 (en) 1995-05-31 1996-05-29 Use of fibroblast growth factors to stimulate bone growth

Country Status (8)

Country Link
US (1) US5656598A (enExample)
EP (1) EP0830138B1 (enExample)
JP (1) JP4804598B2 (enExample)
AT (1) ATE295734T1 (enExample)
AU (1) AU696460B2 (enExample)
CA (1) CA2222217C (enExample)
DE (1) DE69634748D1 (enExample)
WO (1) WO1996038167A1 (enExample)

Families Citing this family (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3639593B2 (ja) * 1993-05-31 2005-04-20 科研製薬株式会社 塩基性線維芽細胞増殖因子含有架橋ゼラチンゲル製剤
WO1998039436A2 (en) * 1997-03-03 1998-09-11 Eisai Co., Ltd. Fibroblast growth factor mutein compositions and methods of use therefor
US6274712B1 (en) 1997-12-23 2001-08-14 3-Dimensional Pharmaceuticals, Inc. Analogs of human basic fibroblast growth factor mutated at one or more of the positions glutamute 89, aspartate 101 or leucine 137
US20030118567A1 (en) * 1999-03-26 2003-06-26 Stewart Duncan John Cell-based therapy for the pulmonary system
CA2266805C (en) 1998-03-27 2015-04-28 An-Go-Gen Inc. Cell-based gene therapy in the treatment of pulmonary disorders
US9585916B2 (en) 1999-03-26 2017-03-07 Northern Therapeutics Inc. Cell based therapy for the pulmonary system
US5929051A (en) * 1998-05-13 1999-07-27 Carrington Laboratories, Inc. Aloe pectins
US7022683B1 (en) 1998-05-13 2006-04-04 Carrington Laboratories, Inc. Pharmacological compositions comprising pectins having high molecular weights and low degrees of methoxylation
US6313103B1 (en) 1998-05-13 2001-11-06 Carrington Laboratories, Inc. Pectic substance as a growth factor stabilizer
ATE250423T1 (de) 1998-07-13 2003-10-15 Univ Southern California Verfahren zur beschleunigen den zuwachs und heilen von knochen und knorpel
US6916783B2 (en) * 1998-07-13 2005-07-12 University Of Southern California Methods for accelerating bone and cartilage growth and repair
US6551355B1 (en) 1998-08-14 2003-04-22 Cambridge Scientific, Inc. Tissue transplant coated with biocompatible biodegradable polymer
DE59903490D1 (de) * 1998-09-11 2003-01-02 Schmidmaier Gerhard Biologisch aktive implantate
DE19846685A1 (de) * 1998-10-09 2000-04-13 Richard Markoll Elektromagnetische Stimulierung von Knorpelgewebe
US6231528B1 (en) 1999-01-15 2001-05-15 Jonathan J. Kaufman Ultrasonic and growth factor bone-therapy: apparatus and method
US6660260B1 (en) * 1999-09-21 2003-12-09 Mayo Foundation For Medical Education And Research Bioprosthetic heart valves
US7494669B2 (en) 2001-02-28 2009-02-24 Carrington Laboratories, Inc. Delivery of physiological agents with in-situ gels comprising anionic polysaccharides
CN1196480C (zh) * 2001-07-03 2005-04-13 北京巨能亚太生命科学研究中心 L－苏糖酸钙在制备预防或治疗骨折的药物中的用途
IL149562A0 (en) 2002-05-09 2002-11-10 Prochon Ltd Fgf variants and methods for use thereof
US20040043089A1 (en) * 2002-09-04 2004-03-04 Rabie A-Bakr M Buguzhi agent and composition and methods of preparing and administering the same
EP1551426B1 (en) * 2002-10-07 2014-06-25 ZymoGenetics, Inc. Methods of administering fgf18
JP2007524376A (ja) * 2003-03-27 2007-08-30 チルドレンズ ホスピタル メディカル センター 軟骨形成を誘導するｆｇｆ−１８タンパク質、標的タンパク質、およびそれぞれをコードするヌクレオチド配列の使用
US7067123B2 (en) 2003-04-29 2006-06-27 Musculoskeletal Transplant Foundation Glue for cartilage repair
US7901457B2 (en) 2003-05-16 2011-03-08 Musculoskeletal Transplant Foundation Cartilage allograft plug
AU2003272814A1 (en) 2003-10-02 2005-05-19 Ibrahim Al-Habdan Peptide for promoting healing of fractures
US8697139B2 (en) 2004-09-21 2014-04-15 Frank M. Phillips Method of intervertebral disc treatment using articular chondrocyte cells
US7837740B2 (en) 2007-01-24 2010-11-23 Musculoskeletal Transplant Foundation Two piece cancellous construct for cartilage repair
US20090319045A1 (en) 2004-10-12 2009-12-24 Truncale Katherine G Cancellous constructs, cartilage particles and combinations of cancellous constructs and cartilage particles
WO2007000884A1 (ja) * 2005-06-29 2007-01-04 National University Corporation Kanazawa University 骨・関節疾患の予防・治療剤およびそのスクリーニング方法
US7815926B2 (en) 2005-07-11 2010-10-19 Musculoskeletal Transplant Foundation Implant for articular cartilage repair
CA2623106C (en) 2005-09-19 2013-12-24 Histogenics Corporation Cell-support matrix having narrowly defined uniformly vertically and non-randomly organized porosity and pore density and a method for preparation thereof
WO2007119240A2 (en) * 2006-04-17 2007-10-25 Hepacore Ltd. Methods for bone regeneration using endothelial progenitor cell preparations
US8962556B2 (en) 2006-09-28 2015-02-24 Prochon Biotech Ltd. FGF-2 variants having N-terminal deletions and increased receptor selectivity and uses thereof
US8435551B2 (en) 2007-03-06 2013-05-07 Musculoskeletal Transplant Foundation Cancellous construct with support ring for repair of osteochondral defects
US20090054984A1 (en) 2007-08-20 2009-02-26 Histogenics Corporation Method For Use Of A Double-Structured Tissue Implant For Treatment Of Tissue Defects
US8685107B2 (en) 2007-07-03 2014-04-01 Histogenics Corporation Double-structured tissue implant and a method for preparation and use thereof
US8945511B2 (en) * 2009-06-25 2015-02-03 Paul Weinberger Sensitive methods for detecting the presence of cancer associated with the over-expression of galectin-3 using biomarkers derived from galectin-3
US20110183311A1 (en) * 2010-01-27 2011-07-28 David Ho Dry platelet preparations for use in diagnostics
US10077420B2 (en) 2014-12-02 2018-09-18 Histogenics Corporation Cell and tissue culture container
WO2018078044A1 (en) * 2016-10-26 2018-05-03 Biointelligence Systems S.L. Bone bioactive composition and uses thereof
KR102245539B1 (ko) 2018-02-12 2021-04-29 주식회사 지앤피바이오사이언스 코어-쉘 구조의 마이크로 입자를 유효성분으로 포함하는 성장인자 유전자 발현 증가용 조성물
US11767511B2 (en) 2018-11-30 2023-09-26 Cellphire, Inc. Platelets as delivery agents
EP3887404A4 (en) 2018-11-30 2022-11-02 Cellphire, Inc. SLIDES LOADED WITH ANTI-CANCER AGENTS
CA3138529C (en) 2019-05-03 2025-10-07 Cellphire, Inc. MATERIALS AND PROCESSES FOR THE PRODUCTION OF BLOOD PRODUCTS
WO2021034719A1 (en) 2019-08-16 2021-02-25 Cellphire, Inc. Thrombosomes as an antiplatelet agent reversal agent
CA3170196A1 (en) 2020-02-04 2021-08-12 Cellphire, Inc. Anti-fibrinolytic loaded platelets
TW202245814A (zh) 2021-02-17 2022-12-01 美商賽菲爾公司 用於治療抗血小板誘導的凝血病之凍乾血小板衍生物組成物
US12702682B2 (en) 2021-11-04 2026-08-11 Cellphire, Inc. Platelet derivative compositions, and methods of making and using such compositions
CN117582485B (zh) * 2023-11-15 2024-06-07 湛江中心人民医院 方格星虫三肽在制备骨质疏松药物中的应用

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL68218A (en) * 1983-03-23 1985-12-31 Univ Ramot Compositions for cartilage repair comprising embryonal chondrocytes
US4868113A (en) * 1986-03-03 1989-09-19 Rorer Biotechnology, Inc. Recombinant DNA vector encoding human endothelial cell growth factor
US5223483A (en) * 1987-10-22 1993-06-29 Merck & Co., Inc. Cysteine-modified acidic fibroblast growth factor
US5312911A (en) * 1987-10-22 1994-05-17 Merck & Co., Inc. Cysteine-modified acidic fibroblast growth factor
US4950483A (en) * 1988-06-30 1990-08-21 Collagen Corporation Collagen wound healing matrices and process for their production
US5077049A (en) * 1989-07-24 1991-12-31 Vipont Pharmaceutical, Inc. Biodegradable system for regenerating the periodontium
AU629316B2 (en) * 1990-04-11 1992-10-01 Flora Inc. Periodontal disease treatment system
EP0499242B1 (en) * 1991-02-15 1996-06-26 Takeda Chemical Industries, Ltd. Stimulation of endosteal bone formation with a cell growth factor
EP0881908B1 (en) * 1994-03-08 2004-06-16 Osteosa Inc. Use of fibroblast growth factors to stimulate bone growth

Also Published As

Publication number Publication date
ATE295734T1 (de) 2005-06-15
EP0830138A4 (en) 2000-10-25
US5656598A (en) 1997-08-12
DE69634748D1 (de) 2005-06-23
EP0830138B1 (en) 2005-05-18
CA2222217A1 (en) 1996-12-05
AU6146496A (en) 1996-12-18
EP0830138A1 (en) 1998-03-25
JPH11506446A (ja) 1999-06-08
CA2222217C (en) 2010-09-14
JP4804598B2 (ja) 2011-11-02
WO1996038167A1 (en) 1996-12-05

Similar Documents

Publication Publication Date Title
US5656598A (en) Use of fibroblast growth factors to stimulate bone growth
AU685619B2 (en) Use of fibroblast growth factors to stimulate bone growth
CA2102429C (en) Bone growth factors and inhibitors of bone resorption for promoting bone formation
US5393739A (en) Use of bone morphogenetic protein in synergistic combination with TGF-β for bone repair
CA2238277C (en) Compositions and therapeutic methods using morphogenic proteins and stimulatory factors
CA2159449C (en) Oesteoblast growth stimulating composition containing pdgf and vitamin d
JP2007197455A (ja) 骨疾患を処置するための骨形成タンパク質
IE66240B1 (en) Composition and method for the treatment of osteoporosis in mammals
EP0384731B1 (en) Osteogenic growth polypeptides identified from regenerating bone marrow
US6352973B1 (en) Bone stimulating factor
CA2061211A1 (en) Stimulation of endosteal bone formation
KÜBLER et al. Bone morphogenetic protein-mediated interaction of periosteum and diaphysis: citric acid and other factors influencing the generation of parosteal bone
US5807822A (en) Insulin-like growth factor II as a pharmaceutical agent in the treatment of osteopenias
US20030027753A1 (en) Bone stimulating factor
BAYLINKtII Ovariectomy selectively reduces the concentration of transforming growth factor p8 in rat bone: Implications for estrogen deficiency-associated bone loss